ObsEva SA (OBSV): Price and Financial Metrics
GET POWR RATINGS... FREE!
OBSV Stock Price Chart Interactive Chart >
OBSV Price/Volume Stats
|Current price||$0.17||52-week high||$3.04|
|Prev. close||$0.15||52-week low||$0.13|
|Day high||$0.17||Avg. volume||1,352,085|
|50-day MA||$0.24||Dividend yield||N/A|
|200-day MA||$1.27||Market Cap||13.24M|
ObsEva SA (OBSV) Company Bio
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women between the ages of 15 and 49 suffering from reproductive health and pregnancy. The company intends to develop treatments for treating endometriosis, uterine fibroids, and preterm labor. The company was founded in 2012 and is based in Switzerland.
Most Popular Stories View All
OBSV Latest News Stream
|Loading, please wait...|
OBSV Latest Social Stream
View Full OBSV Social Stream
Latest OBSV News From Around the Web
Below are the latest news stories about OBSEVA SA that investors may wish to consider to help them evaluate OBSV as an investment opportunity.
H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on ObsEva SA (OBSV - Research Report) today. The company's shares closed yesterday at $0.14.According to TipRanks, Selvaraju is an analyst with an average return of -36.1% and a 13.65% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, Aeterna Zentaris, and Enlivex Therapeutics.Currently, the analyst consensus on ObsEva SA is a Hold with an average price target of $1.00.See the top stocks recommended by analysts >>Based on ObsEva SA's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $32.8 million.
We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them!
After running into a major roadblock at the FDA for its uterine fibroid drug, ObsEva SA (NASDAQ: OBSV) has flagged plans for significant layoffs as part of a wholesale restructuring under the supervision of the supervision court-appointed administrator. In an update, ObsEva plans to lay off approximately 70% of employees, including Katja Buhrer, Chief Strategy Officer. The company intends to complete the terminations in Q4 and shave $7.6 million off its annual expenses. In August, the company sa
$7.6 million annual savings expected via reduction-in-force currently underway$6.2 million savings expected from assignment of legacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd., including $1.7 million of accounts payable assigned to date. Additional assignments are expected in the coming weeks.Company submitted plan to regain compliance with Nasdaq’s minimum stockholders’ equity rule. Additionally, Nasdaq provides notice of noncompliance with Nasdaq’s minimum bid price listi
HC Wainwright has downgraded ObsEva SA (NASDAQ: OBSV) from a Buy to Neutral without a price target. Late last month, the FDA notified ObsEva of review issues regarding deficiencies in the linzagolix application for uterine fibroids. These review issues preclude discussion of labeling and post-marketing commitments at this time. ObsEva said that the resolution of the identified review issues might not be feasible by the September 13 target action date under the Prescription Drug User Fee Act. Acc
OBSV Price Returns